General Information

Previous Page   Next Page

The information in this section is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

This site contains information and education for healthcare professionals.


  1. Explore the importance of TRK fusion proteins as a therapeutic target and understand the clinical use of TRK inhibitors.
  2. Explain the mechanisms behind TRK fusion-driven tumour biology.
  3. Provide an overview of the different techniques used for NTRK gene fusion testing.
  4. Provide recommendations on testing for TRK fusion proteins.

Learning outcomes

The learning outcomes following completion of these modules include:

  • Knowing how and why TRK fusion proteins are a therapeutic target for patients across multiple tumour types.
  • Understand the advantages of genomic profiling for NTRK gene fusions and which patients to test.
  • Ability to interpret genomic profiling results and select the patients most likely to benefit from TRK inhibitor therapy.
  • Knowledge of the clinical data for TRK inhibitors that informs treatment decision making.
  • Knowledge and understanding of the different methodologies used for NTRK gene fusion testing.

Expert contributors

Information included in this website is compiled from review of the medical literature and expert guidance from:

  • Prof. Andrea Sartore-Bianchi: a medical oncologist at Ospedale Niguarda and University of Milano, Italy.
  • Prof. Fernando Lopez-Rios: a molecular and surgical pathologist at Hospital Universitario HM Sanchinarro, Spain.
  • Assoc. Prof. Gerald Prager: a medical oncologist at the Medical University of Vienna, Austria.
  • Dr. Jaclyn Hechtman: a molecular and surgical pathologist at Memorial Sloan Kettering Cancer Center, USA.

Other general information

At the time of publication (2019), there was considered to be an unmet need for information on:

  • How and why TRK fusion proteins are a potential therapeutic target for selected patients across multiple tumour types.
  • Which patients may benefit from TRK inhibitor therapy and, therefore, which patients to test.
  • The different tests available and in development to identify NTRK gene fusions and to select patients who are candidates for TRK inhibitor treatment.
  • Which patients to treat with TRK inhibitors based on genomic profiling results.
  • How to select the right treatment for the right patient using treatment options based on genomic profiling results and available clinical data.